Shilpa Medicare
Shilpa Medicare Limited is an Indian publicly-listed pharmaceutical manufacturer of oncology APIs, generic formulations, biologics, peptides, and specialty polymers, offering integrated CDMO services to global pharmaceutical companies across 100+ countries.
- Company typePublic
- Founded1987
- HeadquartersBangalore, India
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Shilpa Medicare does
Shilpa Medicare Limited is an Indian publicly-listed pharmaceutical company (BSE:530549; NSE:SHILPAMED) founded in 1987 in Raichur, Karnataka, with commercial production starting in November 1989. Operating with 1,001–5,000 employees across six manufacturing facilities, the company runs an integrated pharmaceutical platform spanning chemical synthesis (oncology and non-oncology APIs), peptide manufacturing (SPPS and hybrid), polymer science (PBD-b-PEO, PLGA-b-PGlu, polyorthoesters, hydrogels), continuous flow chemistry, biologics (mammalian CHO/HEK-293 and microbial E. coli/yeast), high-potency API with isolator technology, transdermal patches, and orally disintegrating films. The portfolio reaches patients in 100+ countries, backed by 250+ patent applications filed across IN/PCT, US, EP, JP, AU, CA, and NZ.
The revenue model blends three streams: (1) one-time licensing/API and formulation supply to generic and branded pharma customers globally; (2) CDMO professional services for chemical and biological products from lab to commercial scale; and (3) biosimilar/oncology licensing and royalty income. Customers include global pharmaceutical firms requiring contract manufacturing, regulated-market buyers in the US, EU, and Japan, biologics/biosimilars developers, and specialty pharmaceutical companies needing advanced delivery formats. India-domestic branded generics (SUNISHIL, IBRUSHIL, DASASHIL, Axishil, DMFShil) and consumer products (Swatchshil, Vomistrip, ORAAL, Molshil) reach healthcare providers and patients via standard distribution channels. Go-to-market combines dedicated enterprise business development, regional licensing partners (SteinCares for Latin America, European subsidiary Koanaa Healthcare), and pipeline assets such as OERIS (extended-release ondansetron, Phase 3 with 89% complete response) and the G2B-002 brain-cancer program via Gate2Brain.
The business is anchored by a multi-jurisdictional regulatory dossier footprint (USFDA, EUGMP, TGA, PMDA, KFDA, ANVISA, COFEPRIS, UK MHRA, EAEU, EDQM, Russian MOH) and zero-483 USFDA outcomes at API sites. Recent strategic additions include a fully integrated ADC manufacturing facility at Dharwad (commissioned 2026), equity stakes and development collaborations with Gate2Brain, NXI Therapeutics, mAbTree Biologics, Alveolus Bio, and Orion Corporation, plus a recently appointed COO-Formulations (Dr. Vellaian Karuppiah) from Gland/Strides/Dr. Reddy's/Teva/Wockhardt/Pfizer pedigree. Subsidiaries include Shilpa Biologicals (biologics/ADC/vaccines), Shilpa Biocare, Shilpa Pharma Lifesciences, Shilpa Therapeutics (oral strips), Koanaa Healthcare (Czech Republic), Loba Feinchemie (Austria), and US-based Shilpa Pharma, Inc. and Pilnova Pharma Inc.
Shilpa Medicare firmographics
Firmographics- Name
- Shilpa Medicare
- Legal name
- Shilpa Medicare Limited
- Website
- https://vbshilpa.com
- Company type
- Public
- Founded year
- 1987
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- Shilpa Medicare Limited is an Indian publicly-listed pharmaceutical manufacturer of oncology APIs, generic formulations, biologics, peptides, and specialty polymers, offering integrated CDMO services to global pharmaceutical companies across 100+ countries.
- Ownership category
- akta.pro rank
Where Shilpa Medicare is headquartered
LocationHeadquarters
- HQ city
- Bangalore
- HQ country
- India
- HQ region
- Asia
Offices13 records
Markets served
Shilpa Medicare business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Personnel, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales
Revenue model
- Generic Active Pharmaceutical Ingredients (API): Manufacture and supply of high-quality oncology and non-oncology APIs to pharmaceutical companies globally. Over 55 API products with DMF filings in multiple regulated markets.
- Generic Formulations: Finished dosage forms including injectables, oral solids, transdermal patches, and orally disintegrating strips marketed globally under various regulatory approvals.
- CDMO Services: Contract development and manufacturing organization services providing end-to-end support from lab scale to commercial production for chemical and biological products.
- Biosimilars and Biologics: Development and manufacturing of biosimilar products including monoclonal antibodies, with partnerships for commercialization in international markets.
Go-to-market motion3 records
Distribution channels4 records
Marketing channels5 records
Shilpa Medicare product offering
Product offeringCore offering
Shilpa Medicare develops, manufactures, and supplies active pharmaceutical ingredients (APIs) and finished dosage formulations with a strong focus on oncology products. It also operates as a contract development and manufacturing organization (CDMO) offering chemical synthesis, peptide manufacturing, polymer technology, biologics, and advanced drug delivery (transdermal patches, oral thin films) services to pharmaceutical companies globally.
Product overview
Shilpa Medicare Limited is a pharmaceutical company offering integrated CDMO services and a diversified portfolio of generic APIs, formulations, peptides, polymers, and biologics. The company operates as both a contract development and manufacturing organization (CDMO) and a generic pharmaceutical manufacturer, providing end-to-end capabilities from API synthesis through finished dosage forms. Key product lines include Generic APIs (with over 58 oncology and non-oncology products), Generic Formulations (injectables and oral solids), Peptides (custom, GMP, and generic), Polymers for drug delivery, Biologics including biosimilars, and Transdermal/Oral Thin Film technologies. The company also markets branded generics including oncology drugs (SUNISHIL, IBRUSHIL, DASASHIL, Axishil, DMFShil), consumer products (SwatchShil, Molshil), and specialty formulations. Shilpa Medicare serves regulated markets globally through manufacturing facilities in India with approvals from FDA, EU GMP, PMDA, KFDA, ANVISA, and other regulatory authorities.
Differentiator
Problem solved
Functional benefit
Brands
- OERIS: Once-weekly ondansetron extended-release injection for chemotherapy-induced nausea and vomiting (CINV)
- VOMISTRIP
- SUNISHIL
- IBRUSHIL
- DASASHIL
- AXISHIL
- DMFShil
- Lenshil
- Swatchshil
- Molshil
- Posashil
- ORAAL
- CAPEBEL DT
- Onkoshil
Products and services
- Generic APIs (Oncology and Non-Oncology)
- Generic Formulations
Quantifiable outcome
- 89% complete response rate in Phase 3 CINV trial for OERIS
- +2 more outcomes
Companies that use Shilpa Medicare
Customer profileNamed customers3 records
Segments5 records
Ideal customer profiles4 records
Shilpa Medicare technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature7 records
Shilpa Medicare partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core, strategic and minor.
- Gate2BraincoreShilpa Biocare, a wholly owned subsidiary, invested €7 million for a 30.4% equity stake in Gate2Brain. Shilpa will serve as CMC, manufacturing, and regulatory partner for G2B-002, a first-in-class therapy for pediatric brain cancers (DIPG and pGBM) with Orphan Drug Designation from FDA and EMA. First-in-human trials targeted for FY28.
- SteinCarescoreLicensing agreement for commercialization of a biosimilar across Latin America (30 countries). SteinCares holds exclusive rights for registration, commercialization, and distribution while Shilpa Biologicals handles development and manufacturing from its Dharwad, India facility.
- NXI Therapeutics AGstrategicDevelopment and supply agreement for a New Chemical Entity (NCE) targeting autoimmune and alloimmune disorders. Collaboration includes support for clinical development and GMP manufacturing.
- Dr. Reddy's Laboratoriescore3-year definitive agreement for production-supply of Sputnik V vaccine. Shilpa Biologicals leveraged its biologics manufacturing capabilities for COVID-19 vaccine production.
- Navya Biologicals Pvt. Ltd.strategicAcquired stake in Navya Biologicals to strengthen biologics pipeline and development capabilities.
- Orion Corporation (Finland)strategicStrategic partnership with Orion Corporation for development and manufacturing activities. (Details from press releases section)
- mAbTree Biologics AGstrategicStrategic development partnership for a Novel Immunooncology Asset. Shilpa Biologicals leveraging its biologics capabilities for co-development.
- Alveolus BiominorStrategic partnership to accelerate next-generation lung disease therapies. (Details from press releases section)
Scale indicators15 records
Recent moves6 records
Expansion highlights6 records
Shilpa Medicare competitors and assessment
Company assessmentDirect peers
- Biocon: Indian biopharmaceutical company with strong biosimilars, biologics CDMO, and complex generics franchise. Directly comparable in biologics manufacturing, biosimilars pipeline (insulin, mAbs), and CDMO positioning across regulated markets.
- Piramal Pharma: Indian pharmaceutical and CDMO company with comparable contract manufacturing services, complex generics, and biologics capabilities. Overlapping customer base of global pharma seeking CDMO partners and overlapping geographic reach in regulated markets.
- Aurobindo Pharma: Major Indian generic pharmaceutical manufacturer with strong API manufacturing base, USFDA-approved facilities, and injectable/oncology portfolio. Direct overlap in regulated-market generics and finished dosage forms, particularly in oncology and complex generics.
- Syngene International: Pure-play Indian CDMO offering contract research and manufacturing services for small molecules and biologics. Comparable CDMO service model targeting global pharma clients, with overlapping biologics capabilities and analogous customer base.
- Divi's Laboratories: Leading Indian API manufacturer and contract manufacturer with strong global customer base. Directly comparable in API manufacturing expertise, custom synthesis services, and regulated-market quality compliance.
- Dr. Reddy's Laboratories: Indian pharma major with comparable integrated API+formulations platform and growing biologics/CDMO business. Shilpa has an existing production-supply partnership with Dr. Reddy's for Sputnik V vaccine, indicating direct operational overlap and comparable customer base across global generics and CDMO services.
- Cadila Healthcare (Zydus): Indian pharma major with integrated API, formulations, biosimilars, and consumer healthcare businesses. Direct overlap across oncology generics, biologics pipeline, transdermal/specialty dosage forms, and global market presence.
- Laurus Labs: Indian pharmaceutical manufacturer focused on APIs, formulations, and custom synthesis/CDMO services. Comparable in API manufacturing scale, regulated market focus, and emerging biologics/CDMO ambitions.
- Cipla: One of India's largest pharma companies with strong API, formulations, and emerging biologics footprint. Comparable oncology, complex generics, and CDMO positioning across USFDA, EUGMP, and emerging markets.
Broad incumbents
- Lupin: Larger Indian pharma major with broad generic formulations and API portfolio. Comparable in oncology and complex generics, though with substantially larger scale and broader therapeutic area coverage than Shilpa's oncology-focused portfolio.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Shilpa Medicare social profiles
Digital presenceShilpa Medicare compliance and trust
Trust signalCompliance17 records
Shilpa Medicare financial estimates
Financial estimateRevenue estimate
Valuation estimate
Shilpa Medicare leadership team
Management profileNumber of profiles
Profiles13 records
Shilpa Medicare subsidiaries and ownership
Company hierarchySubsidiaries9 records
Shilpa Medicare funding detail
Funding detailFunding overview
Funding rounds3 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Shilpa Medicare M&A and investment
M&A and investmentM&A1 record
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Shilpa Medicare
What does Shilpa Medicare do?
Shilpa Medicare develops, manufactures, and supplies active pharmaceutical ingredients (APIs) and finished dosage formulations with a strong focus on oncology products. It also operates as a contract development and manufacturing organization (CDMO) offering chemical synthesis, peptide manufacturing, polymer technology, biologics, and advanced drug delivery (transdermal patches, oral thin films) services to pharmaceutical companies globally.
Is Shilpa Medicare a public or private company?
Shilpa Medicare is a public company. It is classified as public and is currently operating.
When was Shilpa Medicare founded?
Shilpa Medicare was founded in 1987. It employs 1,001 to 5,000 people.
Where is Shilpa Medicare based?
Shilpa Medicare is headquartered in Bangalore, India, in the Asia region.
How does Shilpa Medicare make money?
Four revenue lines are on record. Generic Active Pharmaceutical Ingredients (API) is the primary driver. The others are generic Formulations, CDMO Services and biosimilars and Biologics.
Who are Shilpa Medicare's main competitors?
Direct peers on record are Biocon, Piramal Pharma, Aurobindo Pharma, Syngene International, Divi's Laboratories, Dr. Reddy's Laboratories, Cadila Healthcare (Zydus), Laurus Labs and Cipla. Lupin is listed as a broad incumbent.
Does Shilpa Medicare have an API?
No public API is recorded for Shilpa Medicare.